Savara Inc. Stock
Price
Target price
€4.24
€4.24
-0.930%
-0.04
-0.930%
€5.00
19.07.24 / Frankfurt
WKN: A2DQ2B / Symbol: MSTX / Name: Savara / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Savara Inc. Stock
Savara Inc. shows a slight decrease today, losing -€0.040 (-0.930%) compared to yesterday.
The community is currently still undecided about Savara Inc. with 2 Buy predictions and 0 Sell predictions.
As a result the target price of 5 € shows a slightly positive potential of 17.92% compared to the current price of 4.24 € for Savara Inc..
For the coming years our community has positive and negative things to say abot the Savara Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Business model" there were negative voices in the community.
Pros and Cons of Savara Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Savara Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Savara Inc. | -0.930% | -4.505% | 23.977% | 37.662% | -1.852% | 268.696% | 91.077% |
| Rockwell Medical Inc. | -2.220% | -11.523% | -0.116% | -52.288% | -0.807% | -75.739% | -93.713% |
| Gritstone Oncology Inc | 0.770% | 1.427% | -11.307% | -67.941% | -67.492% | -91.052% | - |
| Pacira Pharmaceuticals | -5.260% | -9.091% | -31.298% | -45.122% | -39.597% | -63.115% | -48.820% |
News
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, Phase 3 IMPALA-2
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow